Last checked at 11 May 2023 07:00
Renalytix plc
("Renalytix" or the "Company")
Notice of General Meeting and Posting of Circular
LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General Meeting to be held at the offices of Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p.m. (BST) on 8 June 2023, has today been posted to the Company's shareholders.
An electronic copy of the circular will shortly be available on the Company's website at www.renalytix.com in accordance with AIM Rule 20.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
| ||
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
| |
| ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Shalin Bhamra |
| |
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
CapComm Partners | ||
Peter DeNardo
| Tel: 415-389-6400 or investors@renalytix.com | |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.